National surveillance of antifungal susceptibility of Candida species in South Korean hospitals

Medical Mycology

Volumn 47, Issue 5, 2009, Pages 554-558

  Yoo, Jae Il ^a   Choi, Chi Won ^a   Lee, Kyeong Min ^a   Kim, Young Kwon ^b   Kim, Tae Un ^c   Kim, Eui Chong ^d   Joo, Sae Ik ^d   Yun, Seon Han ^e   Lee, Yeong Seon ^a   Kim, Bong Su ^a  

^a Korea National Institute of Health   (South Korea)

^b Konyang University   (South Korea)

^c Catholic University of Pusan   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

^e Seoul Medical Science Institute   (South Korea)

Author keywords

Antifungal susceptibility; Candida species; Non tertiary hospitals; Tertiary hospitals

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA FAMATA; CANDIDA GLABRATA; CANDIDA HOLMII; CANDIDA HUMICOLA; CANDIDA INTERMEDIA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA RUGOSA; CANDIDA TROPICALIS; CANDIDIASIS; CLAVISPORA LUSITANIAE; CONTROLLED STUDY; DISEASE SURVEILLANCE; HOSPITAL; HUMAN; INCIDENCE; MINIMUM INHIBITORY CONCENTRATION; NON TERTIARY HOSPITAL; NONHUMAN; PHARMACOEPIDEMIOLOGY; PICHIA GUILLIERMONDII; PICHIA JADINII; PUBLIC HEALTH SERVICE; SOUTH KOREA; SPECIES DISTRIBUTION; TERTIARY HEALTH CARE;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; FLUCYTOSINE; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; POPULATION SURVEILLANCE; PYRIMIDINES; REPUBLIC OF KOREA; TRIAZOLES;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS;

EID: 70749091150     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780802354037     Document Type: Article

References (17)

1. Richardson MD. Opportunistic and pathogenic fungi. J Antimicrob Chemother 1991; 28: 1-11.
2. Toscano CM, Jarvis WR. Nosocomial fungal infections. Curr Infect Dis Rep 1999; 1: 347-361.
3. Nucci M, Marr KA. Emerging fungal diseases. Clin Infect Dis 2005; 41: 521-526.
4. Banerjee SN, Emori TG, Culver DH et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med 1991; 91: 86S-89S.
5. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis 1998; 31: 327-332.
6. Cheng MF, Yu KW, Tang RB, et al. Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999. Diagn Microbiol Infect Dis 2004; 48: 33-37.
7. Marichal P, Vanden BH, Odds FC, et al. Molecular biological characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother 1997; 41: 2229-2237.
8. Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 2002; 50: 243-260.
9. Ruhnke M, Eigler A, Tennagen I, et al. Emergence of fluconazoleresistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol 1994; 32: 2092-2098.
10. Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ. SENTRY Participants Group: Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY antimicrobial surveillance program, 1997 to 2000. J Clin Microbiol 2002; 40: 852-856.
11. St-Germain G, Laverdiere M, Pelletier R, et al. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J Clin Microbiol 2001; 39: 949-953.
12. Takakura S, Fujihara N, Saito T, et al. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents includingvoriconazole and micafungin. J Antimicrob Chemother 2004; 53: 283-289.
13. Clinical and Laboratory Standards Institute (formerly NCCLS). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast: Approved Standard M27-A2., Wayne, PA, 2002.
14. Clinical and Laboratory Standards Institute (formerly NCCLS). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast: supplement M27-S2., Wayne, PA, 2006.
15. Basu S, Gugnani HC, Joshi S, Gupta N. Distribution of Candida species in different clinical sources in Delhi, India, and proteinase and phospholipase activity of Candida albicans isolates. Rev Iberoam Micol 2003; 20: 137-140.
16. Foongladda S, Sakulmaiwatana P, Petlum P, Vanprapar N. Candida species, genotypes and antifungal susceptibility of Candida isolates from blood samples of patients at the largest tertiary care hospital in Thailand during 1999-2002. J Med Assoc Thai 2004; 87: 92-99.
17. Yang YL, Cheng HH, Lo HJ. Tsary Hospitals: distribution and antifungal susceptibility of Candida species isolated from different age populations in Taiwan. Med Mycol 2006; 22: 237-242.